An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

Regeneron Pharmaceuticals

Status: Enrolling

Conditions: Chronic Kidney Disease (CKD)

Treatments: Drug: Noninterventional

Study type: Observational

Funder types: Industry

Identifiers

NCT05106387

R5459-RT-1956

Details and patient eligibility

About

The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347).

No study drug will be given during this study.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 [NCT05092347].
2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
3. Willing and able to comply with clinic visits and study-related procedures
4. Provide informed consent signed by study patient or legally acceptable representative

Exclusion criteria

1.There are no exclusion criteria for this study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Trial design

20 participants in 1 patient group

Vonsetamig in study R5459-RT-1944

Description:

Received a kidney transplant and were administered vonsetamig in study R5459-RT-1944 \[NCT05092347\].

Treatment:

Drug: Noninterventional